A legal fight over a single amino acid could set retatrutide's exclusivity window, its Medicare negotiation clock, and its competitive future.
Commentary|Articles|March 6, 2026
From MFN to IRA, Experts Warn of a System Under Pressure in Wide-Ranging Policy Webinar
Author(s)Giuliana Grossi
Fact checked by: Christina Mattina
Experts unpacked MFN drug pricing, expired ACA subsidies, and IRA fallout for community oncology in a recent webinar.
Advertisement
Advertisement
As drug pricing initiatives move forward while coverage policies grow more uncertain, the complexity of the Trump administration’s health care agenda is coming into sharper focus. During a March 3, 2026,
Related to this article
Medicaid expansion was associated with lower colorectal cancer mortality, with the largest reductions in Hispanic patients and stage IV disease.
The trade group says CMS lacks authority to impose GLOBE, which is set to begin January 1.
CMS finalized Transparency in Coverage updates as a researcher warns ghost rates and missing inpatient data limit payer price files.
Amanda Velazquez, MD, discusses GLP-1 formulary strategies, overcoming prior authorization hurdles, and building scalable obesity care infrastructure.
Older adults on Medicare report the best access to care among 10 countries but more cost-related problems and higher out-of-pocket spending.
Even when physicians prescribe guideline-preferred therapies, step therapy and prior authorization can delay or restrict access to CLL therapies.
The study authors note there is an urgent need for "innovative value-based and alternative payment models of care."
Advertisement
Advertisement